Laura Clifton‐Hadley

1.3k total citations
50 papers, 574 citations indexed

About

Laura Clifton‐Hadley is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Laura Clifton‐Hadley has authored 50 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 17 papers in Genetics and 16 papers in Oncology. Recurrent topics in Laura Clifton‐Hadley's work include Lymphoma Diagnosis and Treatment (32 papers), CNS Lymphoma Diagnosis and Treatment (10 papers) and Acute Lymphoblastic Leukemia research (10 papers). Laura Clifton‐Hadley is often cited by papers focused on Lymphoma Diagnosis and Treatment (32 papers), CNS Lymphoma Diagnosis and Treatment (10 papers) and Acute Lymphoblastic Leukemia research (10 papers). Laura Clifton‐Hadley collaborates with scholars based in United Kingdom, United States and Australia. Laura Clifton‐Hadley's co-authors include Amy A. Kirkwood, Pip Patrick, Andrew McMillan, Tim Illidge, John Radford, Peter Hoskin, Peter Johnson, Sally F. Barrington, Clare Rowntree and Kirit M. Ardeshna and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Laura Clifton‐Hadley

46 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laura Clifton‐Hadley United Kingdom	15	325	191	147	141	125	50	574
Ferial Shihadeh United States	10	329 1.0×	255 1.3×	207 1.4×	61 0.4×	98 0.8×	17	576
Edita Kabíčková Czechia	11	295 0.9×	179 0.9×	150 1.0×	96 0.7×	57 0.5×	41	460
Bouthaina S. Dabaja United States	14	358 1.1×	178 0.9×	127 0.9×	49 0.3×	72 0.6×	36	684
Alicia Zhang United States	11	293 0.9×	621 3.3×	57 0.4×	148 1.0×	102 0.8×	16	851
Maricer P. Escalón United States	12	408 1.3×	263 1.4×	81 0.6×	57 0.4×	117 0.9×	22	724
Ahitagni Biswas India	14	195 0.6×	138 0.7×	126 0.9×	81 0.6×	159 1.3×	88	628
Santiago Mercadal Spain	12	567 1.7×	403 2.1×	136 0.9×	66 0.5×	235 1.9×	56	710
Kirsten Herbert Australia	14	251 0.8×	210 1.1×	146 1.0×	54 0.4×	154 1.2×	26	684
L.S. Constine United States	8	168 0.5×	128 0.7×	110 0.7×	69 0.5×	116 0.9×	24	449
Guido Gini Italy	12	241 0.7×	210 1.1×	59 0.4×	64 0.5×	93 0.7×	37	629

Countries citing papers authored by Laura Clifton‐Hadley

Since Specialization

Citations

This map shows the geographic impact of Laura Clifton‐Hadley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Clifton‐Hadley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Clifton‐Hadley more than expected).

Fields of papers citing papers by Laura Clifton‐Hadley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Clifton‐Hadley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Clifton‐Hadley. The network helps show where Laura Clifton‐Hadley may publish in the future.

Co-authorship network of co-authors of Laura Clifton‐Hadley

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Clifton‐Hadley. A scholar is included among the top collaborators of Laura Clifton‐Hadley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Clifton‐Hadley. Laura Clifton‐Hadley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kothari, Jaimal, Toby A. Eyre, Ali Rismani, et al.. (2024). PembroWM : A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's Macroglobulinaemia. British Journal of Haematology. 205(6). 2273–2281. 3 indexed citations

Whitfield, Gillian, Helen Bulbeck, Laura Clifton‐Hadley, et al.. (2024). A Randomised Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1–10 Brain Metastases. Clinical Oncology. 36(11). 681–689. 1 indexed citations

Marzolini, Maria A. V., Wendi Qian, Laura Clifton‐Hadley, et al.. (2024). Quality of life in advanced‐stage, asymptomatic, non‐bulky follicular lymphoma treated with rituximab shows significant improvement compared with watchful‐waiting. British Journal of Haematology. 206(3). 876–886. 2 indexed citations

Tute, Ruth de, Nicholas Counsell, Laura Clifton‐Hadley, et al.. (2024). Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia. Leukemia. 38(4). 822–828.

Rabin, Neil, Shirley D’Sa, Graham Jackson, et al.. (2022). Adjuvant Systemic Therapy in High Risk Solitary Bone Plasmacytoma: Results of the UK Randomised Phase III IDRIS Study (CR UK/14/032). Blood. 140(Supplement 1). 12626–12627. 2 indexed citations

Kothari, Jaimal, Toby A. Eyre, Ali Rismani, et al.. (2022). Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia. Blood. 140(Supplement 1). 3624–3626. 2 indexed citations

Hoskin, Peter, Caroline Brammer, Martin Robinson, et al.. (2021). 4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 22(3). 332–340. 62 indexed citations

Watts, Colin, Keyoumars Ashkan, Michael D. Jenkinson, et al.. (2021). An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma. Cancers. 13(13). 3241–3241. 3 indexed citations

Creasey, Thomas, Sarra Ryan, Amy A. Kirkwood, et al.. (2021). Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials. Haematologica. 107(9). 2051–2063. 14 indexed citations

10.

Moorman, Anthony V., Eleanor J. Ward, Amy A. Kirkwood, et al.. (2021). Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study. Leukemia. 36(3). 625–636. 36 indexed citations

11.

Cutter, David J., Patricia Díez, Georgios Ntentas, et al.. (2021). Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography–Directed Therapy for Early-Stage Hodgkin Lymphoma. Journal of Clinical Oncology. 39(32). 3591–3601. 25 indexed citations

12.

Phillips, Elizabeth H., Catherine Burton, Amy A. Kirkwood, et al.. (2020). Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial. SHILAP Revista de lepidopterología. 1(1). 133–141. 6 indexed citations

13.

McMillan, Andrew, Elizabeth H. Phillips, Amy A. Kirkwood, et al.. (2020). Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. Annals of Oncology. 31(9). 1251–1259. 31 indexed citations

14.

Tute, Ruth de, Andy C. Rawstron, Shirley D’Sa, et al.. (2019). Minimal residual disease (MRD) in Waldenström macroglobulinaemia (WM): Impact on survival outcomes with rituximab-based therapies.. Clinical Lymphoma Myeloma & Leukemia. 19(10). e310–e311. 1 indexed citations

15.

Brazil, L., Angela Swampillai, Allan Hackshaw, et al.. (2018). P01.072 Hydroxychloroquine and short course radiotherapy for elderly patients with glioma: a randomised study. Neuro-Oncology. 20(suppl_3). iii246–iii246. 3 indexed citations

16.

Rule, Simon, Gordon Cook, Nigel H. Russell, et al.. (2018). Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. British Journal of Haematology. 184(6). 999–1005. 25 indexed citations

17.

Latifoltojar, Arash, Shonit Punwani, Andre Lopes, et al.. (2018). Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin’s lymphoma: a comparison with multi-modality reference standard including 18F-FDG-PET-CT. European Radiology. 29(1). 202–212. 31 indexed citations

18.

Kirkwood, Amy A., Massimo Federico, Judith Trotman, et al.. (2017). OUTCOMES OF TREATMENT FOR OBESE PATIENTS WITH ADVANCED HODGKIN LYMPHOMA IN THE RATHL TRIAL (CRUK/07/033). Hematological Oncology. 35(S2). 172–172.

19.

Pike, Lucy, Amy A. Kirkwood, Pip Patrick, et al.. (2017). CAN BASELINE PET‐CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033). Hematological Oncology. 35(S2). 37–38. 17 indexed citations

20.

Brown, Nicholas F., Catherine McBain, Stephen Nash, et al.. (2016). Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. PLoS ONE. 11(5). e0156369–e0156369. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact